Journal of Antimicrobial Chemotherapy (2000) 45, 29
© 2000 The British Society for Antimicrobial Chemotherapy
Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.
University of Alabama at Birmingham, Birmingham, AL, USA
This study determined the comparative in vitro potency of the new investigative quinolone gemifloxacin (SB-265805) using low-passaged clinical isolates and type strains of mycoplasma commonly found in the human respiratory and urogenital tracts. Organisms studied were Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, Mycoplasma penetrans and Ureaplasma urealyticum, obtained from different geographical regions. Comparator drugs were levofloxacin, trovafloxacin, grepafloxacin, azithromycin, clarithromycin, tetracycline and clindamycin. MICs were determined using a microbroth dilution method. The overall range of MICs of gemifloxacin was 
0.008–0.125 mg/L for different Mycoplasma spp. and 0.008–0.5 mg/L for Ureaplasma spp. Depending on the species tested, gemifloxacin showed variable results when compared with the macrolides. However, gemifloxacin was as potent as, or more potent than, tetracycline, clindamycin and the other quinolones investigated.
* Correspondence address. Diagnostic Mycoplasma Laboratory, University of Alabama at Birmingham, 845 19th Street South 609 BBRB, Birmingham, AL 35294, USA. Tel: +1-205-934-9142; Fax: +1-205-975-5965; E-mail: lynn_duffy{at}microbio.uab.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. M. McDevitt Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am. J. Health Syst. Pharm., October 1, 2006; 63(19 Suppl 5): S3 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Waites, N. B. Reddy, D. M. Crabb, and L. B. Duffy Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2541 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Azoulay-Dupuis, J. P. Bedos, J. Mohler, P. Moine, C. Cherbuliez, G. Peytavin, B. Fantin, and T. Kohler Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1046 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pereyre, H. Renaudin, C. Bebear, and C. M. Bebear In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3165 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K Yoo, D. M Triller, C.-S. Yong, and T. P Lodise Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections Ann. Pharmacother., July 1, 2004; 38(7): 1226 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pietra, C. Romagnani, P. Mazzarino, M. Falco, E. Millo, A. Moretta, L. Moretta, and M. C. Mingari HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes PNAS, September 16, 2003; 100(19): 10896 - 10901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Duffy, D. M. Crabb, X. Bing, and K. B. Waites Bactericidal activity of levofloxacin against Mycoplasma pneumoniae J. Antimicrob. Chemother., September 1, 2003; 52(3): 527 - 528. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Waites, D. M. Crabb, and L. B. Duffy In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas Antimicrob. Agents Chemother., January 1, 2003; 47(1): 39 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Waites, D. M. Crabb, X. Bing, and L. B. Duffy In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas Antimicrob. Agents Chemother., January 1, 2003; 47(1): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Sanchez and G. A. Storch Multiplex, Quantitative, Real-Time PCR Assay for Cytomegalovirus and Human DNA J. Clin. Microbiol., July 1, 2002; 40(7): 2381 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|